Archaebiotics: archaea as pharmabiotics for treating chronic disease in humans?

Simple item page
dc.contributor.authorBen Hania, Wajdi
dc.contributor.authorBallet, Nathalie
dc.contributor.authorVandeckerkove, Pascal
dc.contributor.authorOllivier, Bernard
dc.contributor.authorO'Toole, Paul W.
dc.contributor.authorBrugère, Jean-François
dc.date.accessioned2017-12-08T13:33:50Z
dc.date.available2017-12-08T13:33:50Z
dc.date.issued2017
dc.description.abstractRecent findings highlight the role of the human gut microbiota in various disorders. For example, atherosclerosis frequently seems to be the consequence of gut microbiota–derived metabolism of some dietary components. Pharmabiotics (i.e., live/dead microbes and microbe-derived substances) and probiotics (live microorganisms with a health benefit when administered in adequate amounts) are a means to counteract these deleterious effects. Among the latter, microbes now being used or, being currently developed, are bacteria and eukaryotes (yeasts), so omitting the third domain of life—the archaea, despite their unique properties that could be of great interest to human health. Here, we promote the idea that some specific archaea are potential next-generation probiotics. This is based on an innovative example of the bioremediation of a gut microbial metabolite. Indeed, besides the fact that they are archaea (i.e. originating from a domain of life from which no pathogens of humans/animals/plants are currently known), they are rationally selected based on (i) being naturally human-hosted, (ii) having a unique metabolism not performed by other human gut microbes, (iii) depleting a deleterious atherogenic compound generated by the human gut microbiota and (iv) generating a health inert gas.
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationBen Hania, W., Ballet, N., Vandeckerkove, P., Ollivier, B., O’Toole, P. W. and Brugère, J.-F. (2017) 'Archaebiotics: archaea as pharmabiotics for treating chronic disease in humans?', in Sghaier, H., Najjari, A. and Ghedira, K. (eds.) Archaea - New Biocatalysts, Novel Pharmaceuticals and Various Biotechnological Applications. Rijeka: InTech, pp. 41-62. doi: 10.5772/intechopen.69945en
dc.identifier.doi10.5772/intechopen.69945
dc.identifier.endpage62
dc.identifier.journaltitleArchaea - New Biocatalysts, Novel Pharmaceuticals and Various Biotechnological Applicationsen
dc.identifier.startpage41
dc.identifier.urihttps://hdl.handle.net/10468/5161
dc.language.isoenen
dc.publisherInTechen
dc.rights© 2017, The Authors. Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectArchaea
dc.subjectAtherosclerosis
dc.subjectCardiovascular disease
dc.subjectMethanogens
dc.subjectMethanomassiliicoccales
dc.subjectNext-generation probiotics
dc.subjectTrimethylamine
dc.subjectTMA
dc.subjectTrimethylamine oxide
dc.subjectTMAO
dc.subjectTrimethylaminuria
dc.subjectTMAU
dc.titleArchaebiotics: archaea as pharmabiotics for treating chronic disease in humans?en
dc.typeBook chapteren
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
4036.pdf
Size:
3.99 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
Collections
APC Microbiome Ireland - Journal Articles
Microbiology - Journal Articles